List of Excipients in Branded Drug ACTICLATE

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Almirall LLC	ACTICLATE	doxycycline hyclate	16110-501	CELLULOSE, MICROCRYSTALLINE
Almirall LLC	ACTICLATE	doxycycline hyclate	16110-501	CROSCARMELLOSE SODIUM
Almirall LLC	ACTICLATE	doxycycline hyclate	16110-501	FD&C BLUE NO. 1
Almirall LLC	ACTICLATE	doxycycline hyclate	16110-501	FD&C YELLOW NO. 6
Almirall LLC	ACTICLATE	doxycycline hyclate	16110-501	MAGNESIUM STEARATE

Acticlate Excipient Strategy and Commercial Opportunities

Last updated: October 2, 2026

Acticlate is an immediate-release oral doxycycline hyclate tablet marketed by Avion Pharmaceuticals. Its commercial position depends less on active-ingredient exclusivity than on manufacturability, dose flexibility, swallowability, packaging, supply reliability, and the ability to differentiate from generic doxycycline products. The strongest excipient opportunities are low-moisture processing, tablet robustness, taste and throat protection, and differentiated unit-dose packaging.

What is Acticlate and how is it regulated?

Acticlate contains doxycycline hyclate, a tetracycline-class antibacterial. The product is supplied as oral tablets in 75 mg and 150 mg strengths. The FDA-approved labeling identifies the product as an immediate-release tablet and includes standard warnings concerning esophageal irritation, photosensitivity, tooth discoloration, intracranial hypertension, and reduced absorption with polyvalent cations.[1]

Attribute	Acticlate profile
Active ingredient	Doxycycline hyclate
Drug class	Tetracycline antibiotic
Dosage form	Immediate-release oral tablet
Listed strengths	75 mg and 150 mg
Sponsor/marketer	Avion Pharmaceuticals
Administration	Oral
Primary uses	Broad antibacterial indications, subject to current labeling
FDA pathway	Approved prescription drug product
Biosimilar relevance	None; Acticlate is a small-molecule drug
Core competitive issue	Generic doxycycline substitution and price pressure

Doxycycline hyclate is an established active pharmaceutical ingredient with extensive generic competition. The product therefore has limited opportunity to create durable protection through the active ingredient itself. Commercial value is more likely to arise from formulation execution, brand recognition, distribution, packaging, and prescriber or pharmacy preference.

What excipients are used in Acticlate tablets?

The FDA-approved labeling identifies inactive ingredients used to build the tablet core and film coating. The listed excipient platform includes common immediate-release tableting materials such as microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate, and coating components.[1]

Because excipient composition can vary by strength, manufacturing site, and approved labeling revision, the current DailyMed and FDA label should control any product-development or regulatory comparison. The commercial analysis is based on the excipient functions disclosed in the approved labeling rather than on an assumed proprietary formulation.

Functional role of the excipient system

Excipient function	Commercial purpose
Microcrystalline cellulose	Compression aid, tablet filler, mechanical strength
Croscarmellose sodium	Disintegration and rapid drug release
Colloidal silicon dioxide	Glidant and powder-flow improvement
Magnesium stearate	Lubrication during compression
Film-coating polymers and pigments	Identification, swallowability, handling, and appearance

The formulation is consistent with an immediate-release tablet strategy. It does not rely on a complex modified-release matrix, osmotic system, enteric coating, or drug-device combination. That simplicity supports economical manufacturing but limits the potential for formulation-based exclusivity.

How should an excipient strategy be optimized for Acticlate?

The most defensible strategy is to improve process performance without changing the approved release profile or creating unnecessary regulatory risk.

1. Control moisture and chemical degradation

Doxycycline products require disciplined moisture management. Excess moisture can affect powder flow, tablet hardness, dissolution, and chemical stability. The formulation program should evaluate:

• Low-moisture excipient grades
• Water activity rather than only loss-on-drying values
• Hygroscopicity of the tablet core and coating
• Moisture ingress through bottles and blisters
• Stability under high-temperature and high-humidity conditions
• Interaction between the active ingredient and reducing sugars or reactive impurities

Direct compression may reduce aqueous processing exposure. Dry granulation can provide a stronger process-control option where powder flow or content uniformity is inadequate. Wet granulation is commercially feasible but introduces additional moisture and drying variables.

A low-moisture excipient platform can also reduce manufacturing variability. That advantage may be more valuable than a novel excipient claim because generic competition places pressure on cost, yield, and batch-release consistency.

2. Preserve rapid disintegration

Acticlate is an immediate-release tablet. Any excipient change should preserve rapid disintegration and dissolution across the labeled strengths. Croscarmellose sodium or another high-performance superdisintegrant can support tablet breakup, but concentration and addition method matter.

The development program should compare:

• Intragranular versus extragranular disintegrant addition
• Particle-size distribution
• Compression force
• Tablet porosity
• Lubrication time
• Dissolution after accelerated stability
• Performance after exposure to humidity

Over-lubrication with magnesium stearate can reduce wetting and slow dissolution. The formulation should therefore use the lowest validated lubricant level and a controlled blending endpoint.

3. Improve tablet robustness without increasing swallow burden

Doxycycline tablets must withstand manufacturing, bottling, shipping, and pharmacy handling. Higher hardness can improve friability and reduce breakage, but excessive compression may delay disintegration or increase swallowing difficulty.

A commercial formulation should balance:

• Hardness
• Friability
• Tablet thickness
• Edge chipping
• Disintegration time
• Dissolution
• Swallowability
• Score-line performance, if applicable

A thinner tablet with an effective film coat may create a stronger patient proposition than an incremental change in tablet-core excipients.

4. Evaluate coating as a patient-facing excipient platform

Film coating can improve mouthfeel, reduce dusting, support product identification, and reduce direct contact between doxycycline and oral tissues. Coating modifications may support:

• Smoother swallowing
• Reduced tablet odor or taste
• Better visual differentiation between strengths
• Improved resistance to abrasion
• More consistent product appearance

A coating change that materially alters dissolution, stability, or product dimensions may require a more substantial regulatory assessment. A conventional immediate-release film coat is commercially easier to manage than an enteric or extended-release system.

What formulation patents protect Acticlate?

The principal commercial constraint is that doxycycline itself is off-patent and widely available. Publicly accessible product information does not establish a broad, durable patent barrier around the standard Acticlate immediate-release tablet comparable to the protection associated with a novel active ingredient or complex delivery platform.

Protection category	Acticlate opportunity
Active-ingredient patent	Weak or unavailable; doxycycline is an established molecule
Basic immediate-release tablet	Generally difficult to protect broadly
Excipient combination	Possible, but narrow and vulnerable to design-around
Manufacturing process	Potentially protectable if technically distinctive
Packaging system	Potentially protectable through design, trade dress, or utility claims
Method of use	Possible only for specific labeled or clinically supported uses
Trade secret	Relevant for process parameters, supplier specifications, and controls
Trademark and brand	More commercially relevant than active-ingredient patent rights

Patent protection could arise from a narrow composition, a particular manufacturing process, a specific coating, or a packaging configuration. Such claims would need a measurable technical effect, such as improved stability, reduced degradation, controlled dissolution, or manufacturing performance.

An excipient patent strategy should avoid claiming ordinary combinations of microcrystalline cellulose, disintegrant, colloidal silicon dioxide, and magnesium stearate without a credible unexpected result. Those materials are widely used in oral solid dosage forms and are vulnerable to obviousness challenges and formulation design-arounds.

When does Acticlate lose exclusivity?

Acticlate does not have the exclusivity profile of a newly approved drug. Doxycycline has long been subject to generic competition, and the primary commercial risk is substitution by generic doxycycline hyclate products.

Exclusivity type	Acticlate assessment
New chemical entity exclusivity	Not applicable
Orphan-drug exclusivity	Not applicable to the product’s general antibacterial positioning
Pediatric exclusivity	No current basis to treat this as a primary commercial barrier
New formulation exclusivity	Must be confirmed from current FDA records
Patent exclusivity	No broad barrier should be assumed without a live patent and Orange Book review
Generic competition	Established and material

FDA approval of a generic product depends on the reference-listed drug’s regulatory status, applicable patents, exclusivity, and the generic applicant’s ANDA pathway. The existence of a branded product in distribution does not by itself prevent generic approval or pharmacy substitution.[2]

What is the Orange Book status of Acticlate?

The Orange Book identifies reference-listed drugs, approved multisource products, patents submitted by sponsors, and applicable exclusivity information.[2] For Acticlate, the practical questions are:

1. Is Acticlate itself listed as a reference-listed drug for the relevant strength?
2. Are any patents listed against the product?
3. Are those patents active, expired, delisted, or subject to a regulatory challenge?
4. Does the relevant generic applicant rely on Acticlate, another doxycycline product, or a separate reference product?
5. Is therapeutic equivalence rated for the competing product?

Orange Book review should be performed by strength and dosage form. A patent listed against one doxycycline formulation does not automatically protect all doxycycline tablets, capsules, delayed-release products, or suspensions.

Which companies are challenging Acticlate through generic competition?

Generic competition comes primarily from manufacturers of doxycycline hyclate tablets, capsules, delayed-release products, and other oral dosage forms. The competitive set includes established generic companies and contract manufacturers that can supply wholesalers, pharmacies, hospitals, and government purchasers.

The most relevant competitors are not limited to products carrying the Acticlate name. They include:

• Generic doxycycline hyclate immediate-release tablets
• Generic doxycycline capsules
• Delayed-release doxycycline products
• Doxycycline monohydrate products
• Branded and authorized-generic alternatives
• Compounded products in limited institutional settings

A Paragraph IV challenge would matter only if a listed patent covered Acticlate and remained enforceable. Paragraph IV certification is a mechanism for challenging the validity, enforceability, or infringement of an Orange Book-listed patent. It does not apply simply because a generic company seeks approval for doxycycline.[3]

What generic launch risks exist for Acticlate?

Generic launch risk is high because the underlying molecule is mature and manufacturing technology is accessible. The main launch scenarios are:

Scenario	Effect on Acticlate
Additional AB-rated immediate-release tablet	Direct pharmacy substitution and price erosion
Low-cost bottle-pack generic	Wholesale and retail price pressure
Institutional contract award to generic supplier	Volume loss in hospitals and clinics
Product shortage among generic suppliers	Temporary opportunity for branded supply
Doxycycline monohydrate substitution	Prescriber and payer-level competitive pressure
Delayed-release product growth	Differentiation based on gastrointestinal tolerability or dosing convenience

A branded product can retain value if it delivers reliable supply, a preferred package, consistent appearance, pharmacy availability, or a clinically useful strength configuration. Those advantages are commercial rather than exclusionary.

What excipient-led commercial opportunities exist for Acticlate?

Moisture-resistant packaging

Unit-dose blister packaging, high-barrier blister materials, or moisture-controlled bottles could extend stability and reduce exposure to storage conditions. Packaging must be assessed against current shelf life, distribution channels, and pharmacy repackaging practices.

A packaging change can support a commercial claim such as improved handling or dose protection. It does not automatically create patent protection, and the product would need regulatory review if the container-closure system changes.

Patient-friendly tablet design

Potential opportunities include:

• Smaller tablet geometry
• Smoother film coating
• Improved tablet edge design
• Reduced odor and taste
• Clearly differentiated 75 mg and 150 mg presentations
• Unit-dose packaging for adherence and travel

These changes can support dermatology, primary-care, and outpatient prescribing channels where patients often self-administer oral doxycycline for extended periods.

Excipient sourcing and supply resilience

Dual sourcing of microcrystalline cellulose, superdisintegrants, glidants, lubricants, and coating materials can reduce supply interruption risk. Supplier qualification should include:

• Nitrosamine and elemental impurity controls where applicable
• Residual solvent specifications
• Microbial limits
• Particle-size consistency
• Compendial compliance
• Change-notification commitments
• Geographic redundancy

The commercial value of a stable supply chain is high in a mature generic market. A brand that remains available during competitor shortages can gain temporary share without changing the active ingredient.

New dosage-form extensions

Potential extensions include capsules, dispersible tablets, oral suspensions, or delayed-release products. Each would face different competitive and regulatory conditions. A new dosage form can create a stronger product proposition, but it also increases development cost, bioequivalence requirements, manufacturing complexity, and possible competition from existing doxycycline products.

A formulation that reduces esophageal exposure or improves gastrointestinal tolerability could have greater commercial value than a simple excipient substitution. Any such claim would require clinical or comparative evidence and could not be inferred from excipient composition alone.

How does Acticlate compare with other doxycycline products?

Product category	Main differentiation	Patent or exclusivity potential	Commercial risk
Acticlate immediate-release tablet	Brand, 75/150 mg strength options, conventional tablet	Low to moderate, depending on specific claims	High generic substitution
Generic doxycycline hyclate tablet	Low price and broad availability	Low	Direct price competition
Doxycycline monohydrate	Salt and tolerability positioning	Generally low for mature products	Payer and prescriber substitution
Delayed-release doxycycline	Modified release and administration profile	Higher formulation complexity	Competing branded and generic products
Doxycycline capsule	Familiar dosage form and manufacturing simplicity	Low	High substitution risk
Oral suspension	Pediatric or swallowing-use positioning	Potentially higher formulation differentiation	Smaller market and stability burden

Acticlate is better positioned as a reliable, differentiated conventional tablet than as a protected specialty formulation. Its strongest opportunities involve execution, not broad patent exclusivity.

What licensing and partnership opportunities are available?

Licensing opportunities are more likely to involve commercial infrastructure than novel chemistry. Potential transactions include:

• Regional distribution rights
• Authorized-generic supply agreements
• Contract manufacturing with dual-source rights
• Co-development of a patient-friendly dosage form
• Dermatology-channel promotion
• Government and institutional supply contracts
• Packaging or serialization partnerships

A formulation license becomes more attractive if it provides a demonstrable advantage in stability, dissolution, swallowability, or supply cost. A generic excipient blend without performance data is unlikely to support substantial royalty economics.

What is the revenue exposure from Acticlate?

Public product-level revenue for Acticlate is not consistently disclosed by the sponsor. Revenue exposure should therefore be analyzed using prescription volume, average selling price, gross-to-net deductions, channel mix, and generic substitution rather than relying on a reported brand figure.

The main revenue drivers are:

• Number of prescriptions by strength
• Dermatology versus general antibacterial use
• Retail versus institutional volume
• Wholesale acquisition cost
• Rebate and chargeback levels
• Generic availability
• Product shortages
• Pharmacy substitution rates
• Contract manufacturing cost
• Packaging and serialization expense

A mature doxycycline brand normally faces declining price power as generic supply increases. Revenue stability depends on preserving distribution and finding a segment where the branded tablet offers a practical advantage.

Key Takeaways

• Acticlate is an immediate-release doxycycline hyclate tablet marketed in 75 mg and 150 mg strengths.
• The formulation uses conventional tableting excipients, with value concentrated in process control, stability, disintegration, and tablet handling.
• The active ingredient is mature, so broad composition-of-matter exclusivity is not a realistic commercial strategy.
• Generic competition and pharmacy substitution create the principal market risk.
• The strongest formulation opportunities are moisture control, film coating, tablet geometry, packaging, and supply resilience.
• A patent strategy should focus on narrow technical improvements with measurable performance benefits.
• Licensing value is more likely to come from distribution, manufacturing, packaging, or dosage-form extensions than from the existing immediate-release formulation.
• No biosimilar pathway applies because doxycycline is a small-molecule drug.
• Orange Book and FDA records should be reviewed by strength and dosage form before relying on any patent or exclusivity assumption.

FAQs

Is Acticlate a generic drug?

Acticlate is a branded doxycycline hyclate product. Its active ingredient is mature and generic doxycycline products compete directly with it.

Does Acticlate have a unique excipient formulation?

Acticlate uses conventional immediate-release tablet excipients. Any commercial uniqueness must be demonstrated through the exact approved composition, manufacturing process, performance data, or packaging configuration.

Can an excipient change create new patent protection for Acticlate?

Yes, but only if the change supports a patentable technical result, such as materially improved stability, dissolution, manufacturability, or patient performance. Routine excipient substitution is unlikely to provide strong protection.

Are Acticlate and doxycycline monohydrate interchangeable?

They are different doxycycline forms and may have different labeling, formulation, and therapeutic-equivalence considerations. Substitution depends on the specific FDA rating, prescription, and applicable pharmacy rules.

Is Acticlate exposed to Paragraph IV litigation?

Paragraph IV risk depends on whether a relevant Orange Book-listed patent exists and whether a generic applicant certifies against it. The existence of generic doxycycline competition alone does not establish a Paragraph IV case.

References

1. U.S. Food and Drug Administration. (n.d.). Acticlate (doxycycline hyclate) tablets: Prescribing information.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application approvals and patent certifications.
4. U.S. Food and Drug Administration. (n.d.). DailyMed: Acticlate, doxycycline hyclate tablet labeling.